The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Corticosteroids for idiopathic pulmonary fibrosis
Open accessAbstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF), also called cryptogenic fibrosing alveolitis (CFA), is a lethal form of diffuse lung disorder of unknown origin; the mean survival being two to four years. Currently recommended and most prescribed therapy for IPF is based on the use of systemic corticosteroids, even if no formal demonstration of efficacy of this treatment of IPF is available. Furthermore, new insights from pathological studies have produced a new hypothesis, based upon the central role played by aberrant wound healing following repeated lung injury, weakening the rationale basis of the use of corticosteroids in IPF, previously considered simply a chronic inflammatory disease. OBJECTIVES: The objective of the review was to determine the efficacy of corticosteroids in the treatment of adults with IPF. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2002), MEDLINE (January 1966 to May 2002) and EMBASE (January 1985 to December 2002) and reference lists of articles. We searched reference lists of published articles to identify trials. SELECTION CRITERIA: Randomised controlled trials (RCT) and controlled clinical trials (CCT) using corticosteroids alone for the treatment of adults with IPF. DATA COLLECTION AND ANALYSIS: Abstracts of identified articles were retrieved and articles possibly fulfilling inclusion criteria were retrieved in full. Two reviewers would have independently assessed trial quality if there had been any included studies. MAIN RESULTS: Fifteen studies were selected as potentially eligible for meta-analysis. After further analysis of full text papers, no RCTs or CCTs were identified as suitable and therefore no data was available for inclusion in any meta-analysis. All studies were excluded due to inadequate methodologies. REVIEWER'S CONCLUSIONS: At present, there is no evidence for an effect of corticosteroid treatment in patients with Idiopathic pulmonary fibrosis(IPF)/usual interstitial pneumonia (UIP). Given developments in understanding of the pathogenesis of IPF, randomised controlled trials designed to test the efficacy of corticosteroids will probably never be designed. As other forms of pulmonary fibrosis such as non-specific interstitial pneumonia are reported to show a better response to corticosteroids, it is crucial to make an accurate diagnosis in each patient. Moreover, therapies with immunomodulatory rather than anti-inflammatory or immunosuppressive effects may be more promising for the effective treatment of IPF/UIP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Systemic corticosteroids have been widely studied in the treatment of IPF with systematic reviews and meta-analyses failing to show any therapeutic benefit [23,52,53].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [53]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Gross, T. J., & Hunninghake, G. W. (2001) · New England Journal of Medicine · doi:10.1056/nejmra003200 · Cited by 962
Ziesche, R., Hofbauer, E., Wittmann, K., Petkov, V., & Block, L.-H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411703 · Cited by 586
Classification and Natural History of the Idiopathic Interstitial Pneumonias
Kim, D. S., Collard, H. R., & King, T. E. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200601-005tk · Cited by 431
Raghu, G., Depaso, W. J., Cain, K., Hammar, S. P., Wetzel, C. E., Dreis, D. F., Hutchinson, J., Pardee, N. E., & Winterbauer, R. H. (1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/144.2.291 · Cited by 414
Idiopathic Pulmonary Fibrosis: Predicting Response to Therapy and Survival
GAY, S. E., KAZEROONI, E. A., TOEWS, G. B., LYNCH, J. P., GROSS, B. H., CASCADE, P. N., SPIZARNY, D. L., FLINT, A., ANTHONY SCHORK, M., WHYTE, R. I., et al. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9703022 · Cited by 406
Johnson, M. A., Kwan, S., Snell, N. J., Nunn, A. J., Darbyshire, J. H., & Turner-Warwick, M. (1989) · Thorax · doi:10.1136/thx.44.4.280 · Cited by 289
DOUGLAS, W. W., RYU, J. H., & SCHROEDER, D. R. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.9907002 · Cited by 259
Cited by
Items 101–200 of 218
Idiopathic pulmonary fibrosis: Treatment update
O’Connell, O. J., Kennedy, M. P., & Henry, M. T. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0066-5 · Cited by 25
Can exhaled nitric oxide differentiate causes of pulmonary fibrosis?
Guilleminault, L., Saint-Hilaire, A., Favelle, O., Caille, A., Boissinot, E., Henriet, A.-C., Diot, P., & Marchand-Adam, S. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.07.007 · Cited by 23
“In terms of treatment, oral corticosteroid may be used in hypersensitivity pneumonitis (HP), a cause of ILD, but it has little or no effect on IPF [1,5,6].”
BackgroundA comparative study on idiopathic pulmonary fibrosis and secondary diffuse parenchymal lung disease.
Subhash, H. S., Ashwin, I., Solomon, S., David, T., Cherian, A. M., & Thomas, K. (2004) · PubMed · Cited by 22
Fibrocytes and the pathogenesis of diffuse parenchymal lung disease
Mehrad, B., & Strieter, R. M. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-s1-s22 · Cited by 29
Approach to acute exacerbation of idiopathic pulmonary fibrosis
Girdhar, A., Bhatti, H. A., Usman, F., Cury, J., & Bajwa, A. A. (2013) · Annals of Thoracic Medicine · doi:10.4103/1817-1737.109815 · Cited by 24
Hung, C., Tsai, Y.-W., Wu, Y., Yeh, C., & Yang, K. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00850-x · Cited by 22
Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis
Wiertz, I. A., Wuyts, W. A., van Moorsel, C. H. M., Vorselaars, A. D. M., van Es, H. W., van Oosterhout, M. F. M., & Grutters, J. C. (2017) · Respirology · doi:10.1111/resp.13230 · Cited by 23
Nakamura, Y., & Shimizu, Y. (2023) · Cells · doi:10.3390/cells12040548 · Cited by 22
Acute exacerbation of idiopathic pulmonary fibrosis: a 10-year single-centre retrospective study
Yamazoe, M., & Tomioka, H. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000342 · Cited by 21
Aytemur, Z. A., Hacıevliyagil, S. S., İraz, M., Şamdancı, E., Özerol, E., Kuku, İ., Nurkabulov, Z., & Yildiz, K. (2012) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2012.10.002 · Cited by 20
Malayeri, A., Hemmati, A. A., Arzi, A., Rezaie, A., Ghafourian, M., & Khalili, H. (2016) · Jundishapur Journal of Natural Pharmaceutical Products · doi:10.17795/jjnpp-27705 · Cited by 21
“In addition, an ideal drug or combination of drugs is not available (7, 8).”
BackgroundSystemic corticosteroids in fibrotic lung disease: a systematic review and meta-analysis
Pitre, T., Kawano-Dourado, L. B., Kachkovski, G. V., Leung, D., Leung, G., Desai, K., Zhai, C., Adams, W., Funke-Chambour, M., Kreuter, M., et al. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2023-002008 · Cited by 23
Nguyen, T.-H., Nguyen, H.-H.-N., Nguyen, T.-D., Tran, V. T.-H., Nguyen, H. A., & Pham, D. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116496 · Cited by 20
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)
Aribindi, K., Liu, G. Y., & Albertson, T. E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2396121 · Cited by 17
Carter, H. M., Costa, R. M., Adams, T. S., Gilchrist, T. M., Emch, C. E., Bame, M., Oldham, J. M., Huang, S. K., Linderholm, A., Noth, I., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.177072 · Cited by 20
Recent Evidence for Pharmacological Treatment of Idiopathic Pulmonary Fibrosis
Covvey, J. R., & Mancl, E. E. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014551015 · Cited by 20
Dudala, S. S., Venkateswarulu, T. C., Kancharla, S. C., Kodali, V. P., & Dulla, J. B. (2021) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-021-00304-5 · Cited by 19
Segurança e tolerabilidade de Nintedanibe em pacientes com fibrose pulmonar idiopática no Brasil
Pereira, C. A. D. C., Martínez, J. A. B., Baldi, B. G., Jezler, S. F. D. O., Rubin, A. S., Rufino, R., Zonzin, G., Quaresma, M., Trampisch, M., & Rabahi, M. F. (2019) · Jornal Brasileiro de Pneumologia · doi:10.1590/1806-3713/e20180414 · Cited by 25
Therapeutic Update in Idiopathic Pulmonary Fibrosis
Chan, A. L., Rafii, R., Louie, S., & Albertson, T. E. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8244-9 · Cited by 16
“The authors therefore concluded that there was no evidence to support the routine use of corticosteroids alone in the management of IPF [19].”
BackgroundNitrofurantoin-Induced Pulmonary Toxicity: Mechanisms, Diagnosis, and Management
Kaye, A. D., Shah, S. S., LaHaye, L. C., Hennagin, J. A., Ardoin, A. K., Dubuisson, A. M., Ahmadzadeh, S., & Shekoohi, S. (2025) · Toxics · doi:10.3390/toxics13050382 · Cited by 14
Nguyen, J., Armstrong, B. S., Cowman, S. J., Tomer, Y., Veerabhadraiah, S. R., Beers, M. F., & Venosa, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.875887 · Cited by 13
“Because of their complex temporal, spatial and phenotypic heterogeneity, acute inflammatory exacerbations (AIEs) of COPD, asthma, and pulmonary fibrosis are not well characterized or effectively countered with broad-spectrum immunomodulation (corticosteroids, cytokine modulation, anti-TGFβ1) as the current first line…”
BackgroundEaston‐Jones, C. A., Cissell, D. D., Mohr, F. C., Chigerwe, M., & Pusterla, N. (2019) · Equine Veterinary Education · doi:10.1111/eve.13204 · Cited by 13
Nutrition implications of intrinsic restrictive lung disease
Rinaldi, S., Balsillie, C., Truchon, C., Al-Mubarak, A., Mura, M., & Madill, J. (2022) · Nutrition in Clinical Practice · doi:10.1002/ncp.10849 · Cited by 15
Avdeev, S. N. (2015) · PULMONOLOGIYA · doi:10.18093/0869-0189-2015-25-5-600-612 · Cited by 15
Endothelin receptor antagonists – their role in pulmonary medicine
Boniface, S., & Reynaud‐Gaubert, M. (2011) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2009.07.001 · Cited by 12
Miyajima, M., Watanabe, A., Satō, T., Teramukai, S., Ebina, M., Kishi, K., Sugiyama, Y., Kondo, H., Kobayashi, S., Takahashi, Y., et al. (2017) · Surgery Today · doi:10.1007/s00595-017-1605-8 · Cited by 12
Idiopathic Interstitial Pneumonias
King, T. E. (2006) · Humana Press eBooks · doi:10.1007/978-1-59259-963-9_21 · Cited by 12
Nakamura, Y., Shimizu, Y., Fujimaki, M., Uchida, N., Takemasa, A., & Niho, S. (2023) · Biomedicines · doi:10.3390/biomedicines11082259 · Cited by 11
Management of Idiopathic Pulmonary Fibrosis
Cerri, S., Spagnolo, P., Luppi, F., & Richeldi, L. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.11.005 · Cited by 13
Self-citationClinical trials of investigational agents for IPF: a review of a Cochrane report
Richeldi, L. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-s1-s4 · Cited by 12
Self-citationTherapeutic Management of Idiopathic Pulmonary Fibrosis: An Evidence-Based Approach
Nathan, S. D. (2006) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2005.08.004 · Cited by 10
Treating IPF—all or nothing? A PRO‐CON debate
Behr, J., Kolb, M. R. J., & Cox, G. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01645.x · Cited by 11
Macedo, P., Coker, R. K., & Partridge, M. R. (2007) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-7-3 · Cited by 11
Nathan, S. D. (2005) · CHEST Journal · doi:10.1378/chest.128.5_suppl_1.533s · Cited by 10
Sandbo, N. K. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_8 · Cited by 13
Idiopathic pulmonary fibrosis: What primary care physicians need to know
Tolle, L. B., Southern, B. D., Culver, D. A., & Horowitz, J. C. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85a.17018 · Cited by 9
Tuyls, S., Verleden, S. E., Wuyts, W. A., Yserbyt, J., Vos, R., & Verleden, G. M. (2018) · Transplant International · doi:10.1111/tri.13382 · Cited by 10
Interplay between genetics and epigenetics in lung fibrosis
Valand, A., Rajasekar, P., Wain, L. V., & Clifford, R. L. (2025) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2025.106739 · Cited by 11
Ali, K. M., Fattah, F. H. R., Omar, S. H., Gubari, M. I. M., Yousefifard, M., & Hosseini, M. (2020) · Archives of Iranian Medicine · doi:10.34172/aim.2020.116 · Cited by 8
Nakamura, Y., Niho, S., & Shimizu, Y. (2024) · Cells · doi:10.3390/cells13110893 · Cited by 9
Kette, S., Reccardini, N., Salton, F., Confalonieri, P., Andrisano, A. G., Chianese, M. I., Nes, A. D., Maggisano, M., Galantino, A., Nicolosi, S., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18030411 · Cited by 8
Nguyen, Q.-C., Nguyen, H. A., Pham, T.-A. N., Tran, V. T.-H., Nguyen, T.-D., & Pham, D. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118226 · Cited by 9
Jackson, R. M., & Gómez-Marín, O. (2011) · Transplant Research and Risk Management · doi:10.2147/trrm.s16205 · Cited by 9
Xu, C., Wang, P., Lin, C. X., Luo, Z., Huang, Y., Zhao, Z., & Yang, C. (2018) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2018.11.007 · Cited by 7
Fibrosis pulmonar idiopática: estudio diagnóstico con 10 actuaciones clínicas
Morell, F., & Villar, A. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.04.004 · Cited by 7
Interstitial Lung Disease: A Focused Review for the Emergency Clinician
Constantino, K., Gottlieb, M. A., & Long, B. (2023) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2022.10.015 · Cited by 8
Genetic Programs Between Steroid-Sensitive and Steroid-Insensitive Interstitial Lung Disease
Lu, Y., Tang, K., Wang, S., Gao, P., Tian, Z., Wang, M., Chen, J., Xiao, C., Zhao, J., & Xie, J. (2023) · Inflammation · doi:10.1007/s10753-023-01866-7 · Cited by 6
Behr, J., Günther, A., Ammenwerth, W., Bittmann, I., Buhl, R., Eickelberg, O., Ewert, R., Gläser, S., Gottlieb, J., Kreuter, M., et al. (2013) · Cited by 6
Interstitial Lung Disease, Body Mass Index, Energy Expenditure and Malnutrition—a Review
Rinaldi, S., Mura, M., & Madill, J. (2017) · Current Pulmonology Reports · doi:10.1007/s13665-017-0168-x · Cited by 7
Advances in applications of the CRISPR/Cas9 system for respiratory diseases
Ajaykumar, C., Rajkumar, S., Suresh, B., Birappa, G., Gowda, D. A. A., Jayachandran, A., Kim, K.-S., Hong, S.-H., & Ramakrishna, S. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.07.014 · Cited by 5
Cellular therapies for idiopathic pulmonary fibrosis: current progress and future prospects
Le, N. T., Dunleavy, M. W., Kumar, R. D., Zhou, W., Bhatia, S. S., & El-Hashash, A. H. K. (2024) · American Journal of Stem Cells · doi:10.62347/daks5508 · Cited by 5
Idiopathic Interstitial Pneumonias
Selman, M., Morrison, L. D., Noble, P. W., & King, T. E. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4710-0.00057-2 · Cited by 9
Fibrosis pulmonar idiopática: un reto para la atención primaria
Molina, J., Trigueros, J. A., Quintano, J. A., Mascarós, E., Xaubet, A., & Ancochea, J. (2014) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.02.001 · Cited by 5
“Es un inhibidor de la tirosinaquinasa que actúa sobre los factores de crecimiento endotelial vascular, plaquetario y fibroblástico .”
Effect of treatment guidelines on the initial management of idiopathic pulmonary fibrosis
Munson, J. C., Kreider, M. E., Chen, Z., Christie, J. D., & Kimmel, S. E. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03670.x · Cited by 4
Pharmacotherapy in patients with idiopathic pulmonary fibrosis
Nagai, S., Handa, T., & Kim, D. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.11.1909 · Cited by 5
“The fibrosis observed in IPF/UIP specimens is characterized as a temporal heterogeneity without prominent inflammatory cell infiltration (dense fibrosis with collapse of alveoli and prominent fibroblastic foci on the edges adjunct to the dense fibrotic areas) [2-4] .”
BackgroundInfluentialIdentifying Patients with Idiopathic Pulmonary Fibrosis
Richeldi, L., & Abraham, E. H. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200612-1873ed · Cited by 5
Self-citationJoo, S., Lee, S. Y., Lee, S. Y., Hwang, Y., Kim, M., Jeong, J. W., Jang, S. I., & Fang, S. (2024) · BMB Reports · doi:10.5483/bmbrep.2023-0234 · Cited by 4
The road to hell is paved with good intentions: a look back at the PANTHER-IPF trial
Kam, M. L. W., Caliez, J., Nunès, H., & Gille, T. (2022) · Breathe · doi:10.1183/20734735.0074-2022 · Cited by 6
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis
Spagnolo, P., Luppi, F., Montanari, G., & Richeldi, L. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_14 · Cited by 4
Self-citationInnovations thérapeutiques de la fibrose pulmonaire idiopathique
Uzunhan, Y., Nunès, H., Gille, T., Bron, C., Planès, C., & Valeyre, D. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2011.07.009 · Cited by 6
Abdel-Naim, A., Abdel-Hamid, A.-D. E., Dine, R. S. E., Sendker, J., El-Zalabani, S. M. H., Meselhy, M. R., & Jimenez-Negro, E. (2019) · Pharmacognosy Magazine · doi:10.4103/pm.pm_547_18 · Cited by 6
Guleria, R., Chaudhry, D., Singh, V., Kumar, R., Nangia, V., Dhar, R., Agarwal, R., Jindal, A., Madan, K., Behera, D., et al. (2022) · The Indian Journal of Chest Diseases and Allied Sciences · doi:10.5005/ijcdas-60-2-91 · Cited by 7
Antifibrotic therapies for idiopathic pulmonary fibrosis
Akbar, I., Mann, J., Niewodowski, D., Mackintosh, J. A., Glaspole, I., & Barnes, H. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015076 · Cited by 4
Effect of Thalidomide on Cox-2 expression in bleomycin-induced pulmonary fibrosis in mice
Rezaie, M. J., Rostamzadeh, A., Keshavarz, G., Amraei, M., & Moayeri, A. (2019) · Biomedical Research and Therapy · doi:10.15419/bmrat.v6i1.518 · Cited by 3
Marcos, P. J. (2013) · Galicia Clínica · doi:10.22546/22/421 · Cited by 3
Recent trends in interstitial lung disease: Study of 25 cases
Palat, P., & Parmar, H. (2012) · International Journal of Medical Science and Public Health · doi:10.5455/ijmsph.2013.2.52-55 · Cited by 3
“patients of IPF were not given steroid as there is no definitive treatment for it.[9-11] The patients with good PO2 on admission without right sided”
BackgroundMarcos, P. J., Montero, C., & González, I. O. (2013) · Dialnet (Universidad de la Rioja) · Cited by 3
Gotfried, M. H., Girod, C. E., Antin-Ozerkis, D. E., Burgess, T., Strombom, I., Stauffer, J. L., Kirchgaessler, K.-U., & Padilla, M. L. (2018) · Pulmonary Therapy · doi:10.1007/s41030-018-0053-y · Cited by 3
“In past years, patients with IPF were frequently treated with corticosteroids despite a lack of evidence for efficacy or with azathioprine despite weak evidence for efficacy; current treatment guidelines do not recommend these treatments for most patients with IPF [1, 7, 15].”
BackgroundPharmacologic Treatment of IPF
Smargiassi, A., Pasciuto, G., Conte, E. G., Andreani, M., Marra, R., & Richeldi, L. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_13 · Cited by 3
Self-citationLe traitement des fibroses pulmonaires idiopathiques
Dury, S. (2006) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(06)71556-x · Cited by 2
Diffuse Lung Disease: Classification and Evaluation
Collard, H. R., & King, T. E. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9771-5_6 · Cited by 2
Pulmonary fibrosis (idiopathic): Diagnostic study with 10 clinical actions
Morell, F., & Villar, A. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.04.038 · Cited by 2
Les antagonistes des récepteurs de l’endothéline : leur place dans les maladies pulmonaires
Boniface, S., & Reynaud‐Gaubert, M. (2009) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(09)73534-x · Cited by 3
Pneumopathies interstitielles diffuses idiopathiques
Bergeron, A., Tazi, A., & Crestani, B. (2004) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(04)71598-3 · Cited by 2
Corticosteroids May Worsen Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis
Fimognari, F. L., & Pastorelli, R. (2007) · CHEST Journal · doi:10.1378/chest.06-2659 · Cited by 2
Fahim, A. (2021) · The Clinical Respiratory Journal · doi:10.1111/crj.13322 · Cited by 1
Prospects of pirfenidone use in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
Трушенко, Н. В., Levina, I. A., Lavginova, B. B., Suvorova, O., & Avdeev, S. N. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-201 · Cited by 2
Nandawadekar, L. D., Kambhampati, V., Kunuru, S. K., Kuncha, M., Andugulapati, S. B., & Reddy, D. S. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00280 · Cited by 2
Cao, X., Kuang, S., Jiang, K., He, Y., Luo, F., Li, Y., Zhang, M., He, D., & Liang, Q. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1717994 · Cited by 2
“Pulmonary fibrosis (PF), marked by diffuse alveolitis and disruption of the alveolar architecture, is an interstitial lung disease defined by abnormal fibroblast proliferation and excessive deposition of connective tissue (Richeldi et al., 2003).”
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Baroke, E., Maharaj, S. S., & Kolb, M. R. J. (2011) · Clinical Investigation · doi:10.4155/cli.11.155 · Cited by 2
Pathobiology of Novel Approaches to Treatment
Puglisi, S., & Vancheri, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00002-1 · Cited by 1
Loeh, B., Korfei, M., Mahavadi, P., Wasnick, R. M., von der Beck, D., & Günther, A. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10004815 · Cited by 1
Kristiani, M., Djajalaksana, S., Erawati, D. R., Yudhanto, H. S., & Bayuadi, I. (2022) · Malang Respiratory Journal · doi:10.21776/ub.mrj.2022.004.01.2 · Cited by 1
Perspectivas en el tratamiento de la fibrosis pulmonar idiopática
Morell, F., & Villar, A. (2012) · Archivos de Bronconeumología · doi:10.1016/s0300-2896(12)70046-7 · Cited by 1
Nonobstructive Lung Disease and Thoracic Tumors
Pink, K., & Hope‐Gill, B. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6231-8.10050-9 · Cited by 1
Condoluci, C., Inchingolo, R., Mastrobattista, A., Comes, A., Golfi, N., Boccabella, C., & Richeldi, L. (2017) · European Respiratory Society eBooks · doi:10.1183/2312508x.10002017 · Cited by 2
Self-citationKida, Y., Ohshimo, S., Kyo, M., Hosokawa, K., Amatya, V. J., Takeshima, Y., & Shime, N. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.11.09 · Cited by 1
Idiopathic Interstitial Pneumonias
Ryu, J. H., Selman, M., Colby, T. V., & King, T. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00063-4 · Cited by 2
Pathogenic and clinical trial of N-acetylcysteine (Fluimucil) in idiopathic pulmonary fibrosis
Popova, E. N., Bm, K., Резникова, К. У., & Kondarova, O. V. (2005) · PULMONOLOGIYA · doi:10.18093/0869-0189-2005-0-1-34-41 · Cited by 1
Wells, A. U., & Хирани, Н. (2009) · PULMONOLOGIYA · doi:10.18093/0869-0189-2009-4-11-57 · Cited by 2
Application of A Novel Triclustering Method in Analyzing Three Dimensional Transcriptomics Data
Bhar, A. (2015) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5150 · Cited by 1
“A comprehensive list of signaling pathway genes regulated by two TFs in the identified FFLs during the late stage of cellular exposure to estrogen are enlisted in Table 5.4 (see appendix).”
BackgroundMethodInfluentialChapman, J. T. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6643-9.00164-8 · Cited by 1
scRNA-Seq-based drug repurposing targeting idiopathic pulmonary fibrosis (IPF)Preprint
Liu, A., Lee, J., Han, N., & Bender, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.17.508360 · Cited by 2
Mutations in Surfactant Protein C and Interstitial Lung Disease
Panos, R. J., & Bridges, J. P. (2010) · Humana Press eBooks · doi:10.1007/978-1-59745-384-4_6 · Cited by 1
Interstitial lung disease in a female patient with rheumatoid arthritis
Averkieva, Y. V., Raskina, T. A., Степановна, М. О., Volykova, M. A., & Maslova, O. (2014) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2014-1-27-30
Role of lipopolysaccharide in pulmonary inflammation and fibrosis : an in vitro study
Борисова, М. М. (2010)
Diagnóstico y tratamiento de la fibrosis pulmonar idiopática
Ancochea, J., & Valenzuela, C. (2012) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(12)70481-x
Valenzuela, C., Pérez, T. A., Moreno, R. M. G., & Ancochea, J. (2014) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(14)70851-0
Richeldi, L., & Uzunhan, Y. (2011) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(11)70067-2
Self-citationPulmonary hypertension in idiopathic pulmonary fibrosis
Mohammed, A. O., El-Tooney, A. F. S., Taha, N. M., Ghany, H. S. A., & Saied, Z. H. (2014) · Egyptian Journal of Bronchology · doi:10.4103/1687-8426.137348
Metadata
- Authors
- Richeldi, L., Davies, H. R. H. R., Spagnolo, P., & Luppi, F.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Repatriation General Hospital (AU)
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2003-07-21
- Issue
- 3
- Pages
- CD002880-CD002880
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- PMC
- PMC8457302
- OpenAlex
- W1710057076
- Cited by
- 219
- References
- 23
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 9 · 2023: 9 · 2022: 9 · 2021: 8 · 2020: 5 · 2019: 11 · 2018: 12 · 2017: 14 · 2016: 11 · 2015: 11 · 2014: 10 · 2013: 15 · 2012: 10
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, usual interstitial pneumonia, corticosteroids, systemic corticosteroid therapy, treatment efficacy, aberrant wound healing, lung injury, immunomodulatory therapy, nonspecific interstitial pneumonia
- MeSH terms
- Adrenal Cortex Hormones, Adult, Humans, Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.